An investigation of the effects of curcumin on iron overload, hepcidin level, and liver function in β-thalassemia major patients: A double-blind randomized controlled clinical trial

2018 ◽  
Vol 32 (9) ◽  
pp. 1828-1835 ◽  
Author(s):  
Elahe Mohammadi ◽  
Ahmad Tamaddoni ◽  
Durdi Qujeq ◽  
Esmat Nasseri ◽  
Farid Zayeri ◽  
...  
Keyword(s):  
Clinical Trial ◽  
Liver Function ◽  
Iron Overload ◽  
Thalassemia Major ◽  
Controlled Clinical Trial ◽  
Randomized Controlled Clinical Trial ◽  
Double Blind ◽  
Hepcidin Level ◽  
Randomized Controlled

Benefits of Curcumin Supplementation on Antioxidant Status in β-Thalassemia Major Patients: A Double-Blind Randomized Controlled Clinical Trial

2017 ◽  
Vol 71 (3-4) ◽  
pp. 136-144 ◽  
Author(s):  
Esmat Nasseri ◽  
Elahe Mohammadi ◽  
Ahmad Tamaddoni ◽  
Durdi Qujeq ◽  
Farid Zayeri ◽  
...  
Keyword(s):  
Clinical Trial ◽  
Placebo Group ◽  
Antioxidant Status ◽  
Thalassemia Major ◽  
Direct Bilirubin ◽  
Controlled Clinical Trial ◽  
Randomized Controlled Clinical Trial ◽  
Double Blind ◽  
Metabolic Complications ◽  
Randomized Controlled

Background: β-Thalassemia major, the most common inherited anemia in the world, is associated with imbalance in the oxidant-antioxidant system. The objective of this study was to evaluate the efficacy of curcumin supplementation on markers of oxidative stress in patients with β-Thalassemia. Methods: This double-blind randomized controlled clinical trial was performed on 61 β-thalassemia major patients. Subjects in the curcumin group received two 500 mg curcumin capsules daily and patients in the placebo group took 2 placebo capsules daily for 12 weeks. Dietary intakes and biochemical parameters were assessed at the beginning and the end of intervention. Results: At the end of the study, serum malondialdehyde (MDA), total and direct bilirubin significantly decreased (p = 0.002, p < 0.001, and p < 0.001, respectively) and total antioxidant capacity significantly increased (p = 0.005) in the curcumin group. Based on the analysis of covariance, a significant reduction in MDA, total and direct bilirubin was also detected in the curcumin group when compared to the placebo group (p = 0.001, p = 0.039, and p = 0.013, respectively). Changes in hemoglobin, serum iron, ferritin, catalase, and vitamin E were not significant in any of the 2 groups. Conclusions: Curcumin supplementation in combination with deferoxamin improved the antioxidant status in β-thalassemia major patients. Curcumin may be useful for the relief of metabolic complications in these patients.

Sign in / Sign up

Export Citation Format

Share Document